Burris Talks Research and Regulatory Advances in TNBC
Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses immunotherapy, PARP inhibitors, and antibody-drug conjugates, which have become pillars of treatment in triple-negative breast cancer.
Related Articles
FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer
CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.
Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC
HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.
Pembrolizumab Plus Chemo Could Represent New SOC in Advanced/Recurrent Endometrial Cancer
Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.
First-Line Pembrolizumab Plus Chemo Wins Canadian Approval for HER2– Advanced Gastric/GEJ Adenocarcinoma
Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.
FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting.
Functional Precision Medicine Method Aids Treatment Decision-Making in R/R Pediatric Cancers
A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.
FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC
The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.
Y-90 Radioembolization Plus Pembrolizumab Generates Early Efficacy Signals in HCC
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.